Phase II evaluation of vindesine in patients with advanced colorectal carcinoma

D. S. Carroll, R. J. Gralla, N. E. Kemeny

Research output: Contribution to journalArticlepeer-review


Twenty-five patients with metastatic colorectal carcinoma were treated with weekly injections of vindesine. Weakness, leukopenia, paresthesias, and constipation seen in other phase II studies using a weekly treatment schedule were also the major side effects of therapy in this trial. One minor response constituted the only demonstrable therapeutic activity. It can be predicted from the present trial that vindesine, administered weekly at this dose in previously treated patients with advanced colorectal carcinoma, has a true major response rate of <15% (P=0.05). Further studies of vindesine in colorectal carcinoma may be indicated in patients who have not received prior chemotherapy.

Original languageEnglish (US)
Pages (from-to)2097-2098
Number of pages2
JournalCancer Treatment Reports
Issue number11-12
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II evaluation of vindesine in patients with advanced colorectal carcinoma'. Together they form a unique fingerprint.

Cite this